Breaking News

Emisphere Technologies

June 12, 2007

Laura Kragie, M.D., has been appointed vice president of clinical development and chief medical officer, Emisphere Technologies, Inc. Dr. Kragie was previously president and chief scientific officer of Kragie BioMedWorks, a strategic regulatory consulting group. Dr. Kragie will report to Michael V. Novinski, president and chief executive officer of Emisphere Technologies, Inc.

"Dr. Kragie's rich experience as a Medical Officer with the FDA and the Center for Drug Evaluation and Research (CDER) working on regulatory review on a wide array of drug products, along with her deep knowledge of the many facets of biotech, are among the many skills Dr. Kragie brings to Emisphere," said Mr. Novinski. "Dr. Kragie also brings a real sense of business management, deep clinical trial experience and varied pharmaceutical development skills. We are very excited to have her bring this wealth of experience to Emisphere."

At BioMedWorks, Dr. Kragie specialized in pipeline and drug development strategies, efficacy and safety determination, biomarker/surrogate endpoints, intellectual property portfolio development, and regulatory strategies. She guided clients at all stages of their regulatory processes, from pre-IND through to launch and post-approval phases. Dr. Kragie also investigated unmet clinical needs and new indications for approved drugs. Dr. Kragie's research and nonprofit efforts worked to generate and communicate knowledge regarding food, drug and environmental interactions with endocrine systems and their impact on health and disease.
  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems